+

WO2007107594A3 - Derives de trifluoroethanone substitues par un heterocycle a six chainons utilises comme inhibiteurs de la histone desacetylase (hdac) - Google Patents

Derives de trifluoroethanone substitues par un heterocycle a six chainons utilises comme inhibiteurs de la histone desacetylase (hdac)

Info

Publication number
WO2007107594A3
WO2007107594A3 PCT/EP2007/052712 EP2007052712W WO2007107594A3 WO 2007107594 A3 WO2007107594 A3 WO 2007107594A3 EP 2007052712 W EP2007052712 W EP 2007052712W WO 2007107594 A3 WO2007107594 A3 WO 2007107594A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac
inhibitors
histone deacetylase
membered heterocycle
heterocycle substituted
Prior art date
Application number
PCT/EP2007/052712
Other languages
English (en)
Other versions
WO2007107594A2 (fr
Inventor
Philip Jones
Ontoria Jesus Maria Ontoria
Carsten Schultz-Fademrecht
Original Assignee
Angeletti P Ist Richerche Bio
Philip Jones
Ontoria Jesus Maria Ontoria
Carsten Schultz-Fademrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Philip Jones, Ontoria Jesus Maria Ontoria, Carsten Schultz-Fademrecht filed Critical Angeletti P Ist Richerche Bio
Publication of WO2007107594A2 publication Critical patent/WO2007107594A2/fr
Publication of WO2007107594A3 publication Critical patent/WO2007107594A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) : ainsi que des sels et des tautomères pharmaceutiquement acceptables de ceux-ci. Les composés de la présente invention sont des inhibiteurs de la histone désacétylase(HDAC) et sont utiles pour traiter des maladies à prolifération cellulaire, y compris le cancer. Ils sont également utiles pour traiter les maladies neurodégénératives, la déficience mentale, la schizophrénie, les maladies inflammatoires, la resténose, les troubles immunitaires, le diabète, les maladies cardiovasculaires et l'asthme.
PCT/EP2007/052712 2006-03-21 2007-03-21 Derives de trifluoroethanone substitues par un heterocycle a six chainons utilises comme inhibiteurs de la histone desacetylase (hdac) WO2007107594A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0605573.5 2006-03-21
GBGB0605573.5A GB0605573D0 (en) 2006-03-21 2006-03-21 Therapeutic Compounds

Publications (2)

Publication Number Publication Date
WO2007107594A2 WO2007107594A2 (fr) 2007-09-27
WO2007107594A3 true WO2007107594A3 (fr) 2008-09-12

Family

ID=36293110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/052712 WO2007107594A2 (fr) 2006-03-21 2007-03-21 Derives de trifluoroethanone substitues par un heterocycle a six chainons utilises comme inhibiteurs de la histone desacetylase (hdac)

Country Status (2)

Country Link
GB (1) GB0605573D0 (fr)
WO (1) WO2007107594A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070020A2 (fr) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Expression genique relative a la sensibilite au gefitinib, produits et procedes associes
JP5422120B2 (ja) 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
RU2015124002A (ru) 2012-11-20 2017-01-10 Вертекс Фармасьютикалз Инкорпорейтед Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы
CN103214413B (zh) * 2013-03-22 2015-05-13 郑州泰基鸿诺药物科技有限公司 一种含杂环的三氟甲基酮化合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075929A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibiteurs de l'histone déacétylase
WO2003076401A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives d'amino-sulfonyle utilises comme inhibiteurs de l'histone deacetylase
US20060058553A1 (en) * 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058553A1 (en) * 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase
WO2003075929A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibiteurs de l'histone déacétylase
WO2003076401A1 (fr) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives d'amino-sulfonyle utilises comme inhibiteurs de l'histone deacetylase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASAMI, K.; ET AL.: "Antimicrobial activity of trifluoromethyl ketones and their synergism with promethazine", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 18, 2001, pages 161 - 165, XP002488062 *

Also Published As

Publication number Publication date
GB0605573D0 (en) 2006-04-26
WO2007107594A2 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2006061638A3 (fr) Derives heterocycliques utilises comme inhibiteurs d'histone desacetylase (hdac)
WO2008075172A3 (fr) Dérivés de nicotinamide
WO2007029035A3 (fr) Derives de trifluoroethanone a substitution thiophene et thiazole utilises comme inhibiteurs de l'histone desacetylase (hdac)
WO2007072080A3 (fr) Dérivés cétone à hétérocycles substitués en tant qu’inhibiteurs de l’histone désacétylase (hdac)
WO2008132139A3 (fr) Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
WO2007092095A3 (fr) Composes de pyrimidinyl benzothiophene
WO2012066578A3 (fr) Composés 4-(sélénophèn-2(ou 3)-ylamino)pyrimidines substitués et leurs procédés d'utilisation
WO2010046445A3 (fr) Dérivées d’urée de nortropanes substitués, médicaments contenant de tels composés et leur utilisation
WO2010151710A3 (fr) Composés hétérocycliques substitués utilisés en tant qu'inhibiteurs de la kinase et leur procédé d'utilisation
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2008060621A3 (fr) Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
WO2009030952A3 (fr) Composés hétérocycliques et leurs procédés d'utilisation
WO2010043953A3 (fr) Nouveaux composés cycliques pontés en tant qu'inhibiteurs de l'histone désacétylase
WO2009011850A3 (fr) Nouveaux composés thérapeutiques
WO2010144499A3 (fr) Dérivés d'urée comme inhibiteurs de kinase
WO2008035359A3 (fr) Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2008012338A3 (fr) Nouvelles formulations
PH12015501640A1 (en) Azole benzene derivative
WO2008000421A3 (fr) Composés organiques
WO2009082526A3 (fr) Antagonistes de ccr1 hétérocycliques à substitution benzylique d'ortho-pyrrolidine pour les maladies auto-immunes et l'inflammation
MX2010002900A (es) Derivados heterociclicos triciclicos.
WO2007052073A3 (fr) Derives d'amide de soufre et d'amide a heterocycle substitue utilises en tant qu'inhibiteurs d'histone desacetylase (hdac)
WO2006134499A3 (fr) Derives de 2-(1h-indolylsulfanyl)-aryl amine
WO2007107594A3 (fr) Derives de trifluoroethanone substitues par un heterocycle a six chainons utilises comme inhibiteurs de la histone desacetylase (hdac)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07727188

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07727188

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载